Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Quince Therapeutics Inc QNCX

Healthcare Biotechnology
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s... see more

Recent & Breaking News (NDAQ:QNCX)

Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer's Population

Business Wire March 21, 2022

ROSEN, A LEADING LAW FIRM, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - CRTX

PR Newswire March 15, 2022

Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Newsfile March 15, 2022

Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors

Business Wire March 15, 2022

Cortexyme to Present New GAIN Trial Data at AD/PD 2022

Business Wire March 14, 2022

Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders

Business Wire March 9, 2022

Cortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588

Business Wire March 8, 2022

CRTX INVESTOR NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - CRTX

Newsfile March 6, 2022

ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - CRTX

Newsfile March 1, 2022

CORTEXYME ALERT: Bragar Eagel & Squire, P.C. is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm

Business Wire February 24, 2022

CORTEXYME ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm

Business Wire February 23, 2022

ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - CRTX

Newsfile February 22, 2022

ROSEN, LEADING INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - CRTX

Newsfile February 20, 2022

Investigation Notice: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 18, 2022

Investigation Alert: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 17, 2022

SHAREHOLDER ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - CRTX

PR Newswire February 16, 2022

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 16, 2022

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

Business Wire February 15, 2022

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

Business Wire February 14, 2022

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - CRTX

Business Wire February 14, 2022